Recently, results published from the randomized, phase 3 BFORE trial in The Lancet reported that Bosutinib might be a more effective as the first-line therapy than imatinib for patients with newly diagnosed chronic myeloid leukemia (CML). A total of 536 patients with newly diagnosed chronic-phase CML were enrolled and randomly assigned (1:1) in the study. The patients were assigned to a once-daily treatment with either 400 mg bosutinib or 400 mg imatinib.
A major molecular response (MMR) was considered as the primary endpoint. Results: Among the total patients, the number of patients who achieved MMR was significantly higher with bosutinib than with imatinib (47·2% [95% CI 40·9–53·4] vs 36·9% [30·8–43·0]; odds ratio [OR] 1·55 [95% CI 1·07–2·23], p=0·020). Comparatively, more patients in the bosutinib group as compared to imatinib group achieved a complete cytogenetic response (77·2%…
